Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Similar articles for PubMed (Select 19483651)

1.

Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function.

Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT.

J Immunother. 2009 Jul-Aug;32(6):585-92. doi: 10.1097/CJI.0b013e3181a8efe6.

2.

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S.

Cancer Res. 2005 Apr 15;65(8):3336-46.

3.

Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.

Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.

Eur J Pharmacol. 2008 Sep 4;591(1-3):43-51. doi: 10.1016/j.ejphar.2008.06.026. Epub 2008 Jun 12.

PMID:
18588872
4.

Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.

Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D.

Breast Cancer Res. 2012 Feb 21;14(1):R35.

5.
6.

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ.

Cancer Res. 2006 Jul 1;66(13):6589-97.

8.

Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.

Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, Monni O.

BMC Genomics. 2008 Jul 24;9:348. doi: 10.1186/1471-2164-9-348.

9.

Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.

Collak FK, Yagiz K, Luthringer DJ, Erkaya B, Cinar B.

J Biol Chem. 2012 Jul 6;287(28):23698-709. doi: 10.1074/jbc.M112.358713. Epub 2012 May 22.

10.

Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT.

EMBO J. 1996 Oct 1;15(19):5256-67.

11.

G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.

Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH.

Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91. Epub 2004 Mar 17.

12.

Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.

Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL.

Clin Cancer Res. 2008 May 1;14(9):2543-50. doi: 10.1158/1078-0432.CCR-07-0321.

13.

Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.

Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM.

Neuro Oncol. 2012 Mar;14(3):315-25. doi: 10.1093/neuonc/nor209. Epub 2011 Dec 12.

14.

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.

Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.

Cancer Res. 2009 Apr 15;69(8):3520-8. doi: 10.1158/0008-5472.CAN-08-4884. Epub 2009 Apr 7.

15.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR.

Cancer Res. 2005 Aug 15;65(16):7052-8.

16.

LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.

Li C, Liu VW, Chan DW, Yao KM, Ngan HY.

Int J Gynecol Cancer. 2012 Jan;22(1):15-22. doi: 10.1097/IGC.0b013e3182322834.

PMID:
22080879
17.

Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells.

Park EJ, Min HY, Chung HJ, Hong JY, Kang YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, Lee SK.

Cancer Lett. 2009 May 18;277(2):133-40. doi: 10.1016/j.canlet.2008.11.029. Epub 2009 Jan 9.

PMID:
19135778
18.

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.

Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK.

Mol Cancer Ther. 2009 Aug;8(8):2204-10. doi: 10.1158/1535-7163.MCT-09-0160. Epub 2009 Aug 11.

19.

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.

Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.

Prostate. 2004 Feb 15;58(3):259-68.

PMID:
14743465
20.

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y.

Oncol Rep. 2012 Jun;27(6):1703-9. doi: 10.3892/or.2012.1724. Epub 2012 Mar 15.

PMID:
22426819
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk